An approach to plan and evaluate the location of radiotherapy services and its application in the New South Wales, Australia.

Comput Methods Programs Biomed

SMART Infrastructure Facility, Engineering and Information Sciences, University of Wollongong, Wollongong, NSW 2522, Australia.

Published: November 2015

This paper proposes an integrated modelling approach for location planning of radiotherapy treatment services based on cancer incidence and road network-based accessibility. Previous research efforts have established travel distance/time barriers as a key factor affecting access to cancer treatment services, as well as epidemiological studies have shown that cancer incidence rates vary with population demography. Our study is built on the evidence that the travel distances to treatment centres and demographic profiles of the accessible regions greatly influence the uptake of cancer radiotherapy (RT) services. An integrated service planning approach that combines spatially-explicit cancer incidence projections, and the placement of new RT services based on road network based accessibility measures have never been attempted. This research presents a novel approach for the location planning of RT services, and demonstrates its viability by modelling cancer incidence rates for different age-sex groups in New South Wales, Australia based on observed cancer incidence trends; and estimations of the road network-based access to current NSW treatment centres. Using three indices (General Efficiency, Service Availability and Equity), we show how the best location for a new RT centre may be chosen when there are multiple competing locations.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cmpb.2015.08.005DOI Listing

Publication Analysis

Top Keywords

cancer incidence
20
radiotherapy services
8
south wales
8
wales australia
8
approach location
8
location planning
8
treatment services
8
services based
8
road network-based
8
incidence rates
8

Similar Publications

Background: Oropharyngeal cancer (OPC) incidence is rising globally, predominantly in high-income countries due to human papillomavirus (HPV) infection. However, further data on OPC incidence in Brazil is needed. The aim of this study was to estimate the incidence, trends, and predictions of OPC in Brazilian population-based cancer registries (PBCRs) by period, sex, and topography.

View Article and Find Full Text PDF

External Validation of a 5-Factor Risk Model for Breast Cancer-Related Lymphedema.

JAMA Netw Open

January 2025

Institute of Medical Science, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.

Importance: Secondary lymphedema is a common, harmful side effect of breast cancer treatment. Robust risk models that are externally validated are needed to facilitate clinical translation. A published risk model used 5 accessible clinical factors to predict the development of breast cancer-related lymphedema; this model included a patient's mammographic breast density as a novel predictive factor.

View Article and Find Full Text PDF

Purpose Of Review: This paper reviewed the current literature on incidence, clinical manifestations, and risk factors of Chimeric Antigen Receptor T-cell (CAR-T) cardiotoxicity.

Recent Findings: CAR-T therapy has emerged as a groundbreaking treatment for hematological malignancies since FDA approval in 2017. CAR-T therapy is however associated with a few side effects, among which cardiotoxicity is of significant concern.

View Article and Find Full Text PDF

Causal role of ischemic heart disease in ovarian cancer subtypes.

Discov Oncol

January 2025

Department of Cardiovascular Medicine, Jiu Jiang NO.1 People's Hospital, Jiujiang, 332000, China.

Background: Ischemic heart disease (IHD) may share biological mechanisms with cancer, including ovarian cancer, through pathways such as chronic inflammation and oxidative stress. However, the relationship between IHD and ovarian cancer subtypes remains unclear. This study used Mendelian randomization (MR) to explore potential causal associations.

View Article and Find Full Text PDF

Rare cancer survivorship research funding at the National Institutes of Health (NIH), 2017 to 2023.

Cancer Causes Control

January 2025

Office of Cancer Survivorship, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA.

Purpose: Rare cancers are defined as those for which there are less than 15 cases per 100,000 in the population annually. While much progress in detection and treatment has been made over the past decade for many rare cancers, less progress has been made in understanding survivorship needs. The objective of this study was to characterize the National Institutes of Health (NIH) cancer survivorship grant portfolio focused on rare cancers and to identify gaps specific to this area of science.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!